Symmetry Investments LP Buys Shares of 10,162 Moderna, Inc. (NASDAQ:MRNA)

Symmetry Investments LP purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 10,162 shares of the company's stock, valued at approximately $423,000.

Other hedge funds have also modified their holdings of the company. Wilmington Savings Fund Society FSB boosted its position in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC lifted its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. Crowley Wealth Management Inc. purchased a new stake in Moderna in the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRNA has been the topic of several analyst reports. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Citigroup started coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Finally, Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of "Hold" and an average target price of $58.70.

Moderna Stock Performance

Shares of MRNA stock traded down $0.02 during trading hours on Monday, reaching $27.21. The company had a trading volume of 2,989,000 shares, compared to its average volume of 7,347,033. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of -2.92 and a beta of 2.23. The stock has a fifty day moving average of $30.19 and a 200-day moving average of $38.37.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.